In the Pipeline: Non-Specialty Drugs to Watch in 2021
COVID-19 vaccines are just one type of medication seeing significant development. Learn about the most important non-specialty drugs coming this...
COVID-19 vaccines are just one type of medication seeing significant development. Learn about the most important non-specialty drugs coming this...
Despite the pandemic, manufacturers are continuing to develop new drugs, especially specialty medications. Read on for the most important...
Recent data shows patients with chronic conditions are largely driving health care spending, yet many plans are seeing suboptimal outcomes. So,...
How a company conducts business and what policies and procedures it has in place will determine how successful it will be as a partner to your...
To kick off the new year, Navitus' CEO, David Fields, shares his industry insights on what plan sponsors should watch for in 2021.
Hear first-hand how Texas Association of Counties (TAC) fine-tuned its Rx benefit plan performance and experienced significant savings. Watch the...
What are the latest developments with the COVID-19 vaccines? In this blog, we’ll discuss the current state of the COVID-19 vaccinations and what...
Drug benefits comprise more than 20% of overall healthcare costs, which represents a large portion of a plan sponsor’s budget.1 For many plan...
Reducing spend is important, but shouldn't be your only priority when selecting a PBM. Chief Growth Officer Byron Mickle explains why strong...
Nearly 150 million people in the U.S. have at least one chronic illness, and as many as half fail to take their prescriptions appropriately.1,2
Copyright © 2018 Navitus
All rights reserved